Эффективность и безопасность пероральной низкодозовой аллерговакцины АВ-2П у пациентов с атопической бронхиальной астмой
Л. Р. Выхристенко, С. В. Огризко, Vera B. Laporevich et al. · Медицинские новости · 2013
A randomized, open prospective in the parallel-group study was performed with 62 patients. Study group included 40 patients who received low-dose oral allergovaccine AV-2P, in the second group included 22 patients who received standard drug treatment of atopic bronchial asthma. Study duration was 7 months. The primary end points were clinical signs and medication of asthma, and secondary variables were quality of life. Receiving oral allergovaccine AV-2P helped increase the control of symptoms of asthma, which was achieved in 87.9% of cases, reducing the need for β 2-agonists to 22,5%, in inhalation glucocorticosteroids by 31,8%, reducing the number of asthma exacerbations, improve the quality of life of patients with asthma. Low-dose oral allergovaccine AV-2P reduces the symptoms of asthma, prevents exacerbation and has high safety
Cited by 0 works.